Download Files:
DMHCA
SKU
HY-129098-10 mg
Category Reference compound
Tags LXR, Metabolic Disease, Metabolic Enzyme/Protease;Vitamin D Related/Nuclear Receptor
$60 – $350
Products Details
Product Description
– DMHCA, a potent and selective LXR agonist, specifically activates the cholesterol efflux arm of the LXR pathway without stimulating triglyceride synthesis. DMHCA has anti-inflammatory effects and can be used for the research of cholesterol homeostasis diabetes[1].
Web ID
– HY-129098
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Metabolism-sugar/lipid metabolism
Molecular Formula
– C26H43NO2
References
– [1]Cristiano P Vieira, et al. Selective LXR agonist DMHCA corrects retinal and bone marrow dysfunction in type 2 diabetes. JCI Insight. 2020 Jul 9;5(13):e137230.
CAS Number
– 79066-03-8
Molecular Weight
– 401.63
Compound Purity
– 99.52
SMILES
– C[C@@]12[C@](CC[C@]2([H])[C@H](C)CCC(N(C)C)=O)([H])[C@@]3([H])[C@@](CC1)([H])[C@@]4(C(C[C@H](CC4)O)=CC3)C
Clinical Information
– No Development Reported
Research Area
– Metabolic Disease
Solubility
– DMSO : 7.69 mg/mL (ultrasonic)
Target
– LXR
Pathway
– Metabolic Enzyme/Protease;Vitamin D Related/Nuclear Receptor
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.